)
Kodiak Sciences (KOD) investor relations material
Kodiak Sciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved positive Phase 3 topline results for GLOW2 study, demonstrating efficacy and safety of Zenkuda in diabetic retinopathy.
Completed enrollment in Phase 3 DAYBREAK study for Zenkuda and KSI-501 in wet AMD; topline data expected September 2026.
Advanced KSI-101 with strong Phase 1b APEX results in MESI and ongoing Phase 3 PEAK and PINNACLE studies.
Expanded pipeline with bispecific antibody candidates and progress in digital health/AI initiatives.
Financial highlights
Ended 2025 with $209.9 million in cash and cash equivalents.
Net loss for Q4 2025 was $56.7 million ($1.04/share), compared to $44.1 million ($0.84/share) in Q4 2024.
Full-year 2025 net loss was $230.0 million ($4.32/share), up from $176.2 million ($3.35/share) in 2024.
Completed $173.0 million equity offering in December 2025.
Outlook and guidance
Intends to accelerate multi-indication BLA submission for Zenkuda based on strong GLOW2 data.
Topline DAYBREAK data for Zenkuda and KSI-501 expected in Q3 2026; PEAK and PINNACLE topline data for KSI-101 expected in Q4 2026 and Q2 2027, respectively.
Current cash expected to fund operations into 2027.
- Late-stage retina therapies show strong efficacy and durability, targeting major unmet needs.KOD
Corporate presentation16 Mar 2026 - Lead retinal programs advance to pivotal trials with improved efficacy and strong financial backing.KOD
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Advancing three late-stage retinal programs with durable, multi-mechanism therapies and strong funding.KOD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Late-stage pipeline advances with enhanced ABCD platform, strong cash, and key data in 2025–26.KOD
R&D Day 202420 Jan 2026 - Enhanced formulations and pivotal studies set the stage for major 2025–2026 clinical milestones.KOD
Jefferies London Healthcare Conference 202413 Jan 2026 - Late-stage retina assets advance toward pivotal data and launches, with strong financial runway.KOD
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Pivotal phase III trials for enhanced Tarcocimab and KSI-501 approach major data readouts.KOD
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026 - Late-stage pipeline and enhanced biologics drive growth prospects in retinal disease markets.KOD
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Multiple pivotal phase III readouts and strong KSI-101 efficacy set up a transformative year.KOD
Evercore ISI 8th Annual HealthCONx Conference11 Dec 2025
Next Kodiak Sciences earnings date
Next Kodiak Sciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)